Thermo Fisher Scientific VEGF-165 Polyclonal Antibody, Biotin, PeproTech

Applications

Tested Dilution

Publications

Western Blot (WB)

0.1-0.2 µg/mL

-

ELISA (ELISA)

0.25-1.0 µg/mL

-

Immunostaining (IS)

-

View 1 publication 1 publication

Product Specifications

Species Reactivity

Mouse

Published species

Mouse

Host/Isotype

Rabbit

Class

Polyclonal

Type

Antibody

Immunogen

E.coli-derived, 39.0 kDa Recombinant Murine VEGF 165

Conjugate

Biotin Biotin Biotin

Form

Lyophilized

Concentration

0.1-1.0 mg/mL

Purification

Antigen affinity chromatography

Storage buffer

PBS

Contains

no preservative

Storage conditions

-20°C

Shipping conditions

Ambient

Product Specific Information

AA Sequence of recombinant protein: MAPTTEGEQK SHEVIKFMDV YQRSYCRPIE TLVDIFQEYP DEIEYIFKPS CVPLMRCAGC CNDEALECVP TSESNITMQI MRIKPHQSQH IGEMSFLQHS RCECRPKKDR TKPEKHCEPC SERRKHLFVQ DPQTCKCSCK NTDSRCKARQ LELNERTCRC DKPRR.

Preparation: Produced from sera of rabbits immunized with highly pure Recombinant Murine VEGF 165. Anti-Murine VEGF 165-specific antibody was purified by affinity chromatography and then biotinylated.

Sandwich ELISA: To detect Murine VEGF 165 by sandwich ELISA (using 100 µL/well antibody solution) a concentration of 0.25-1.0 µg/mL of this antibody is required. This biotinylated polyclonal antibody, in conjunction with PeproTech Polyclonal Anti-Murine VEGF 165 (500-P131) as a capture antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant Murine VEGF 165.

Western Blot: To detect mVEGF by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 µg/mL. Used in conjunction with compatible secondary reagents the detection limit for Recombinant mVEGF is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.

500-P131BT-1MG will be provided as 2 x 500 µg

Target Information

The vascular endothelial growth factor (VEGF) family currently includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and PIGF. VEGF and its receptor system have been shown to be the fundamental regulators in the cell signaling of angiogenesis. Most tumors have the absolute requirement of angiogenesis and VEGF has been described as the most potent angiogenic cytokine linked to this process. To date 5 different isoforms of VEGF have been described. These isoforms are generated as the result of alternative splicing from a single VEGF gene. These various isoforms have been shown to bind to two tyrosine-kinase receptors flt-1 (VEGFR-1) and flk-1/KDR (VEGFR-2), which have been found to be expressed almost exclusively on endothelial cells.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.